Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704162 | 0.88 | FPR2 (0.46) | FPR2ALDH1A1 | |
| SCHEMBL9900612 | 0.86 | FPR2 (0.38) | FPR2 | |
| SCHEMBL1703915 | 0.80 | FPR2 (0.50) | FPR2 | |
| SCHEMBL9901605 | 0.79 | FPR2 (0.49) | FPR2 | |
| SCHEMBL27930825 | 0.78 | FPR2 (0.40) | FPR2ALDH1A1 | |
| SCHEMBL27832762 | 0.77 | FPR2 (0.36) | FPR2 | |
| SCHEMBL9900144 | 0.76 | FPR2 (0.46) | FPR2ALDH1A1 | |
| SCHEMBL9900171 | 0.74 | FPR2 (0.37) | FPR2ALDH1A1 | |
| SCHEMBL2328492 | 0.74 | FPR2 (0.33) | FPR2 | |
| SCHEMBL9901446 | 0.74 | FPR2 (0.36) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648724-B1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| EP-2648724-A1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| CN-103249413-A | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2013-08-14 | — | — | CN | disclosed |
| WO-2012077051-A1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | ADORA1, ADORA3, HCAR3 | FPR2 333/4885ALDH1A1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.